Integrative omics has posed new challenges in modern precision medicine, particularly in oncology, including i) the identification of new tumor markers for early, precise, and non-invasive diagnostics, and ii) the discovery of innovative molecular targets for therapeutic applications. Our studies on medulloblastoma, a highly malignant childhood tumor, have contributed to identifying RNA molecules that meet these criteria.
Technologies
In this section it is possible to view, also through targeted research, the technologies inserted in the PROMO-TT Database. For further information on the technologies and to contact the CNR Research Teams who developed them, it is necessary to contact the Project Manager (see the references at the bottom of each record card).
Displaying results 1 - 4 of 4
In our recent publication we identified a group of bladder cancer-specific ncRNA, called T-UCRs that are the most up-regulated in bladder cancer patient samples compared with normal bladder urothelium.
Plants can compete favorably with traditional expression systems (mammalian cells, yeasts or bacteria) to produce recombinant proteins/peptides of pharmaceutical/industrial/agrifood interest. This technology names “Plant Molecular Farming”. The CNR-IBBA research team offers the study of new strategies for the expression and optimization of recombinant proteins/peptides in plant-based systems (plant tissues, transgenic plants, plant cell culture). Our pipeline is based on the following modules:
SITODIET is an innovative software that supports a translational approach to health’s state. It integrates various sources of physiological, behavioral, and psychological data to reduce the risks associated with the onset of lifestyle-related diseases (primary prevention), to support health professionals in early diagnosis (secondary prevention) or to manage the personalized therapy’s patient (tertiary prevention). SITODIETcollects data automatically, through actigraphy tools, as wristband or smartwatch, or manually